Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency

PURPOSE: Intravenous IgG (IVIG) treatment wear-off is commonly experienced by patients, who report increased susceptibility to infection, and decreased quality of life towards the end of their 3- or 4-week dosing cycle, when serum IgG levels approach their trough. We quantified IVIG wear-off in term...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojavin, Mikhail A., Hubsch, Alphonse, Lawo, John-Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792336/
https://www.ncbi.nlm.nih.gov/pubmed/26910102
http://dx.doi.org/10.1007/s10875-016-0243-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792336/
https://www.ncbi.nlm.nih.gov/pubmed/26910102
http://dx.doi.org/10.1007/s10875-016-0243-z

Ejemplares similares